Ivacaftor

Results: 106



#Item
11David Jack, CEO Cystic Fibrosis Australia  PBAC deferral disappointing, but not the end of the road Cystic Fibrosis Australia (CFA) has been advised that the Pharmaceutical Benefits Advisory Committee (PBAC

David Jack, CEO Cystic Fibrosis Australia PBAC deferral disappointing, but not the end of the road Cystic Fibrosis Australia (CFA) has been advised that the Pharmaceutical Benefits Advisory Committee (PBAC

Add to Reading List

Source URL: www.cysticfibrosis.org.au

Language: English - Date: 2013-08-22 00:17:11
1203 SeptemberTo the Cystic Fibrosis Community in Australia, It has been a very busy and important period for the cystic fibrosis community in Australia. The deferral of Kalydeco by the Pharmaceutical Benefits Advis

03 SeptemberTo the Cystic Fibrosis Community in Australia, It has been a very busy and important period for the cystic fibrosis community in Australia. The deferral of Kalydeco by the Pharmaceutical Benefits Advis

Add to Reading List

Source URL: www.cysticfibrosis.org.au

Language: English - Date: 2013-09-03 02:49:21
13Friday 20 DecemberPBAC Recommends Subsidy for Kalydeco Confirmation this evening that the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the inclusion of Kalydeco on the Pharmaceutical Benefits

Friday 20 DecemberPBAC Recommends Subsidy for Kalydeco Confirmation this evening that the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the inclusion of Kalydeco on the Pharmaceutical Benefits

Add to Reading List

Source URL: www.cysticfibrosis.org.au

Language: English - Date: 2013-12-22 19:01:39
14Your name Your address Phone number Email Date Their name

Your name Your address Phone number Email Date Their name

Add to Reading List

Source URL: www.cysticfibrosis.org.au

Language: English - Date: 2014-07-14 00:09:06
15Chapter Chat  W I N T E R

Chapter Chat W I N T E R

Add to Reading List

Source URL: www.cff.org

Language: English - Date: 2012-02-01 17:31:42
16  	
   	
     	
   	
  

           

Add to Reading List

Source URL: www.cysticfibrosis.org.au

Language: English - Date: 2013-07-09 21:43:03
17Microsoft Word - Document1

Microsoft Word - Document1

Add to Reading List

Source URL: www.cysticfibrosis.org.au

Language: English - Date: 2013-02-27 19:54:31
18Patients want intervention on KALYDECO | PharmaDispatch ­ PharmaDispatch ­ http://www.pharmadispatch.com ­

Patients want intervention on KALYDECO | PharmaDispatch ­ PharmaDispatch ­ http://www.pharmadispatch.com ­

Add to Reading List

Source URL: www.cysticfibrosis.org.au

Language: English - Date: 2014-03-13 21:53:10
19FDA questions benefit of cystic fibrosis drug from Vertex (Update)

FDA questions benefit of cystic fibrosis drug from Vertex (Update)

Add to Reading List

Source URL: medicalxpress.com

Language: English - Date: 2015-05-18 04:50:25
20Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (G551D mutation) Reference: NHS England A01/P/a 1

Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (G551D mutation) Reference: NHS England A01/P/a 1

Add to Reading List

Source URL: www.england.nhs.uk

Language: English - Date: 2015-01-14 05:46:19